Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT05806372 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Biomarkers of CVD Dysfunction in Hypertensive Disorders of Pregnancy

Start date: October 15, 2023
Phase:
Study type: Observational

Profound and concomitant cardiovascular hemodynamic changes, necessary to support fetoplacental development and its increasing supply demands, occur during a physiological pregnancy characterized by an increase in cardiac output, heart rate and plasma volume, and fall in vascular resistance and blood pressure. The result of these changes is a volume overload that will lead to a compensatory transient left ventricular eccentric hypertrophy. This, together with the pro-inflammatory state typical of pregnancy, represents the pregnancy as a stress-test for the maternal cardiovascular system. Pregnancies complicated by hypertensive disorders of pregnancy (HDP), particularly those with early onset and/or complicated by intrauterine fetal growth restriction (FGR), are characterized by a cardiovascular maladaptation. Women who experienced HDP in pregnancy, especially pre-eclampsia (PE), more often develop later in life ischemic heart disease, hypertension and stroke, obesity, dyslipidemia, and end-stage renal disease. Regardless its clinical impact, very little knowledge is available on the mechanisms by which PE could lead to cardiovascular disease (CVD), and, especially, to heart failure after pregnancy. Preliminary results suggest a cross-talk between pregnancy-induced biomarkers and cardio-vascular system. Particularly, cultures of neonatal rat cardiomyocytes and fibroblasts were used to investigate the role of the serum of women with HDP in regulating their proliferation. 5-ethynyl-2'-deoxyuridine (EdU) was administered to label DNA synthesis in proliferating cells. After 3 days of in vitro culture, EdU incorporation was analyzed upon immunofluorescence staining using specific antibodies by high content microscopy. A possible protective effect exerted by the selected sera against apoptosis was evaluated, as well, by Caspase activation. Moreover, the effect of cardiomyocytes and fibroblasts proliferation and apoptosis on maternal hemodynamic parameters was evaluated using median regression models. These data show that the serum of women with HDP triggers a net increase in the percentage of proliferating cardiomyocytes compared to controls. Moreover, there were relationship between cardiomyocytes and fibroblasts proliferation and maternal hemodynamics parameters thus, supporting the hypothesis that the serum of women with HDP may contain factors capable of stimulating cardiac cells in response to the cardiovascular stress-test

NCT ID: NCT05802134 Completed - Clinical trials for Cardiovascular Diseases

Increased Access to Fruits and Vegetables for Hypertension in Immigrant Hispanic/Latinx Individuals

Start date: March 28, 2023
Phase: N/A
Study type: Interventional

The goal of this observational study is to learn about the effect improved access to culturally-appropriate fruits/vegetables has on cardiometabolic markers, specifically systolic blood pressure and markers of adiposity in immigrant Hispanic/Latinx individuals with hypertension and obesity. The secondary aim is to determine compliance to the increased F/V intake recommended by the Dietary Approaches to Stop Hypertension (DASH) Diet by assessing changes in skin carotenoid status. The main question it aims to answer is whether consuming 8-10 servings of culturally-appropriate, carotenoid-containing F/V daily for 4 weeks to meet the requirements of the DASH Diet supported by diet and lifestyle education will result in reductions in systolic BP and decreased markers of adiposity (body weight, Body Mass Index, and waist circumference).

NCT ID: NCT05800145 Active, not recruiting - Hypertension Clinical Trials

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

SMART-FI
Start date: May 16, 2023
Phase: N/A
Study type: Interventional

In the US, 47% of adults have hypertension (HTN), and HTN accounts for more cardiovascular disease (CVD) deaths than any other CVD risk factor. Thus, the lack of an adaptive, stepped-care intervention to address FI in patients with HTN is a critical problem affecting a large, vulnerable population.

NCT ID: NCT05798975 Recruiting - Hypertension Clinical Trials

Analysis of Heart Rate Variability After a Physical Exercise Session

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Systemic arterial hypertension (SAH) is a multifactorial clinical condition, characterized by sustained elevation of blood pressure levels, contributing to 50% of deaths from cardiovascular disease. The Autonomic Nervous System (ANS) plays a fundamental role in the regulation of Blood Pressure (BP) and is closely associated with Heart Rate (HR). HR changes are called Heart Rate Variability (HRV). In individuals with SAH, HRV indices are reduced compared to normotensive individuals, showing changes in autonomic modulation, thus increasing the risk for cardiovascular events. The objective of this study will be to analyze the Heart Rate Variability in individuals with controlled SAH after a session of aerobic (EA) or resistance (RE) physical exercise.

NCT ID: NCT05798923 Recruiting - Clinical trials for Pulmonary Hypertension

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

Start date: April 3, 2023
Phase: Phase 2
Study type: Interventional

This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.

NCT ID: NCT05798481 Recruiting - Hypertension Clinical Trials

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the sublingual space. The generated SNOAC rapidly diffuses into blood circulation thereby decrease the systemic blood pressure. This compound can be an alternative to organic nitrate NO donor drugs without developing tolerance in patients.

NCT ID: NCT05798442 Not yet recruiting - Obesity Clinical Trials

The Impact of Using a Smartphone Health Application in the Improvement of Cardiovascular Disease Risk Factors

Start date: January 30, 2024
Phase: N/A
Study type: Interventional

This study investigates the effectiveness of Mobile health application (mHealth apps) in the improvement of cardiovascular disease risk factors including metabolic and behavioral factors. The app will be tested on patients with any of the modifiable risk factors of CVD such as hypertension, obesity, hyperlipidemia, and impaired glycemic control/type 2 diabetes mellitus .

NCT ID: NCT05798208 Completed - Hypertension Clinical Trials

Effect of Covid-19 on Hypertension

Start date: February 15, 2020
Phase:
Study type: Observational

In this single center , retrospective study, 5355 covid patient were selected from 2020 to 2022, with recorded blood pressure before covid and recording after covid. Blood pressure before and after covid were compared, by pair T test.

NCT ID: NCT05796648 Active, not recruiting - Obesity Clinical Trials

Preparing a Food Is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Hypertension and obesity are both major risk factors for cardiovascular disease (CVD), a leading cause of death for Black women in the United States. The investigators propose examining the feasibility and acceptability of the 12-week RN-CHeFRx (Real Nourishment and Cooking Healthy Food is Rx) intervention - grocery delivery, cooking classes, and nutrition education - for Black women with hypertension and obesity to improve nutritious eating habits and blood pressure control.

NCT ID: NCT05795829 Recruiting - Clinical trials for Uncontrolled Essential Hypertension

Ultrasound Ablation for Essential Hypertension(FIM)

Start date: January 16, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and feasibility of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in the treatment of essential hypertension.